Status
Conditions
Treatments
About
The purpose of this study is to examine the efficacy and performance of the variant of Defocus Incorporated Spectacle lenses on controlling myopia progression in fast progressing myopic children.
Full description
The variant of Defocus Incorporated Spectacle lenses (DG2) is a multifocal spectacle lens that produces myopic defocus images and corrects distance refractive errors at the same time.
Participants will be randomly allocated to either single vision lens group (control) or the variant of Defocus Incorporated Spectacle lens (DG2) group (treatment). After 12 months of lens wear, the SV lens prescribed to the control group will be replaced with the DG2 lens and be monitored for another 12 months. In parallel, the DG2 treatment groups will continue their corresponding intervention for 12 months. Their cycloplegic refraction and axial length will be monitored every 6 months over 2 years. The changes in refractive errors and axial length in two groups will be compared.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
SER: -1.00D or below
Documented history of fast progressing myopia, either in SER or AL
Best-corrected monocular visual acuity (VA) in both eyes: 0.00 logMAR (equivalent) or better
Acceptance of random group allocation and the masked study design
Anisometropia of 1.50 D or less
Astigmatism of 2.00 D or less
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
118 participants in 2 patient groups
Loading...
Central trial contact
Dennis Yan Yin Tse, PhD; Rachel Ka Man Chun, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal